Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients (Q82443669)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21074370%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21074370%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

S. Christian Cheatham

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074370

26 August 2024

Katherine M. Shea

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074370

26 August 2024

Daniel P. Healy

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074370

26 August 2024

Melissa L. Humphrey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074370

26 August 2024

Megan R. Fleming

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074370

26 August 2024

Matthew F. Wack

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074370

26 August 2024

David W. Smith

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074370

26 August 2024

Kevin M. Sowinski

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074370

26 August 2024

Michael B. Kays

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074370

26 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21074370

26 August 2024

publication date

11 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21074370%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

16 January 2020

https://api.elsevier.com/content/article/PII:S0924857910003882?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

https://api.elsevier.com/content/article/PII:S0924857910003882?httpAccept=text/plain

26 August 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

International Journal of Antimicrobial Agents

26 August 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21074370%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21074370%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21074370%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

46-50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21074370%20AND%20SRC:MED&resulttype=core&format=json

Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).

16 January 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.

26 August 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance

26 August 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

26 August 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

26 August 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

26 August 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa

26 August 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function

26 August 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms

26 August 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

26 August 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.

26 August 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.

26 August 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia

26 August 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.

26 August 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Prediction of creatinine clearance from serum creatinine

26 August 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

A high performance liquid chromatography system for the simultaneous assay of some antibiotics commonly found in combination in clinical samples

26 August 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).

26 August 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).

26 August 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance

26 August 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.

26 August 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

26 August 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy

26 August 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.

26 August 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects

26 August 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.016

26 August 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21074370%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference